Clinical trial NCT06692439: Acute Heart Failure in Elderly Patients Admitted to the Emergency Department with Acute Dyspnea: a Multimarker Approach Prognostic Study
Official title: Acute Heart Failure in Elderly Patients Admitted to the Emergency Department with Acute Dyspnea: a Multimarker Approach Prognostic Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Acute Heart Failure (AHF)
Dyspnoea
Keywords: acute heart failure
dyspnea
prognosis
biomarkers
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2024-11-18
Enrollment: 185
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients aged ≥75 years admitted to the ED for acute dyspnea

Brief summary: Background and Rationale:

Acute dyspnea is a frequent presenting symptom in emergency departments (ED), with acute heart failure (AHF) being the most common cause leading to hospitalization in elderly patients. AHF in this population presents unique challenges in diagnosis, management, and risk stratification. Current tools for severity assessment and risk stratification (NT-proBNP and echocardiography) have shown limited evolution over the past 20 years and remain insufficient, particularly for elderly patients who predominantly present with heart failure with preserved ejection fraction (HFpEF). Recent European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines specifically call for research on biomarkers within a multi-marker strategy for AHF risk stratification.

Research Hypothesis:

The study hypothesizes that a combination of biomarkers (NT-proBNP, High-sensitivity Troponin I, ST2, Galectin-3, CD146 and suPAR) will provide prognostic value and effectively stratify risk for early outcomes (90-day mortality and hospital readmission) in patients aged ≥75 years presenting to the ED with acute dyspnea and diagnosed with AHF.

Primary Objective:

To evaluate the prognostic value of six biomarkers, both individually and in combination, for predicting 90-day all-cause mortality or ED readmission in elderly patients (≥75 years) presenting with acute dyspnea and diagnosed with AHF.

Study Design:

This is a prospective prognostic study including patients from 7 emergency departments from university and non-university hospitals in France.

Study Population:

(I) Patients aged ≥75 years presenting to the ED with acute dyspnea meeting at least two criteria:

* Respiratory rate ≥25/min
* PaO2 ≤70 mmHg
* SpO2 ≤92% on room air
* PaCO2 ≥45 mmHg and pH ≤7.35
* Oxygen requirement

(ii) Have confirmed AHF diagnosis by two expert reviewers based on clinical data, laboratory results (excluding NT-proBNP), ECG, imaging, and specialized cardiac echo

Primary Endpoint:

Composite endpoint of 90-day all-cause mortality or ED readmission, as recommended by the ESC for evaluating early outcomes in AHF patients.

Analysis plan includes:

* ROC curves for optimal biomarker thresholds
* Kaplan-Meier survival analysis with log-rank tests
* Univariate and multivariate Cox regression analyses
* Bootstrap methods for confidence intervals


Eligibility criteria: Inclusion Criteria: Patients aged ≥75 years from the READ cohort (NCT04240067) who:

1. Present to the ED with acute dyspnea meeting at least two criteria:

   * Respiratory rate ≥25/min
   * PaO2 ≤70 mmHg
   * SpO2 ≤92% on room air
   * PaCO2 ≥45 mmHg and pH ≤7.35
   * Oxygen requirement
2. Have confirmed AHF diagnosis by two expert reviewers based on clinical data, laboratory results (excluding NT-proBNP), ECG, imaging, and specialized cardiac echo
3. Provided written consent for data use in the READ-MA-PRONO study

Exclusion Criteria:

* No written consent for data use in the READ-MA-PRONO study

Primary outcomes:
measure: Composite endpoint of 90-day all-cause mortality or ED readmission, as recommended by the ESC for evaluating early outcomes in AHF patients.
timeFrame: 90-day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: CHU Besançon
name: Frédéric MAUNY, MD, PhD
role: STUDY_CHAIR
affiliation: CHU Besançon
name: Marc PUYRAVEAU, MSc
role: STUDY_CHAIR
References: